“Our team is dedicated to finding and telling you more about the products and deals we love. If you love them too and decide to purchase through the links below, we may receive a commission. Pricing and availability are subject to change.”
“Our team is dedicated to finding and telling you more about the products and deals we love. If you love them too and decide to purchase through the links below, we may receive a commission. Pricing and availability are subject to change.”
A lawyer for relatives of people killed in the 2014 downing of Malaysia Airlines Flight 17 over eastern Ukraine told a court hearing Thursday that 290 relatives and partners of the victims have filed compensation claims for “emotional distress" against the four suspects charged in the downing. Lawyer Arlette Schijns was speaking at a preliminary hearing in the long-running legal proceedings against three Russians and a Ukrainian charged with involvement in shooting down the Amsterdam-to-Kuala Lumpur flight on July 17, 2014. None of the suspects have appeared in court and the case is proceeding in their absence.
Norway will take more time to assess whether to resume the use of the AstraZeneca vaccine against COVID-19 or stop it altogether, health minister Bent Hoeie said on Thursday. Norway's Institute of Public Health recommended ending the use of the AstraZeneca vaccine, but the government needs more information before making a final decision, he said. Authorities on March 11 suspended the rollout of the vaccine after a small number of younger inoculated people were hospitalised for a combination of blood clots, bleeding and a low count of platelets, some of whom later died.
Susan Kostro has joined Safety National as Director – Public Entity Underwriting.
In AM Best’s four-part series, "The Greening of Insurance Asset Management," top industry leaders discuss how the insurance asset management sector is adapting to meet emerging standards and expectations for climate risk and social responsibility.
Sales increase driven by first sales of COVID-19 Antigen Rapid Test in Europe after January 2021 CE Mark approval Awarded two new patents for InFoods® diagnostic guided therapy technology, including the first Japanese patent InFoods® IBS diagnostic-guided therapy clinical trial expecting top line trial results by the third calendar quarter of 2021 IRVINE, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced its fiscal third quarter 2021 financial results for the three months ended February 28, 2021. The Company reported consolidated sales of $3.62 million for the fiscal third quarter of 2021, compared to $1.18 million for the same period in fiscal 2020, an increase of 208%. The increase in revenues during the quarter was primarily due to sales of the Company’s 15-minute COVID-19 Antigen Rapid Test in Europe, after its January 2021 CE Mark approval, as well as increased sales for several of the Company’s other diagnostic products. For the nine months ended February 28, 2021, consolidated net sales for Biomerica increased 55% to $6.14 million compared to $3.97 million for the same period in fiscal 2020. The Company’s cost of sales for fiscal third quarter 2021, included an exceptionally large inventory reserve of approximately $1.43 million. Gross margin excluding this exceptionally large inventory reserve would have been 38%. During the quarter the company increased its investment in research and development which is largely focused on several COVID-19 tests and ongoing development of the InFoods® IBS product. The Company incurred higher general and administrative expenses, mainly due to higher reserves, and increased legal, personnel and consulting costs related to the Company preparing for anticipated growth related to the InFoods® Technology, and possible commercialization of other products in the pipeline. Net loss for the fiscal third quarter 2021 was $1.84 million compared to a net loss of $0.86 million for the same period in fiscal 2020. During the fiscal third quarter, the Company recorded a receivables reserve of $0.29 million and recorded a non-cash charge of $0.24 million for stock-based compensation related to the annual equity (stock option) awards granted to its Board of Directors and senior managers. Excluding the exceptionally large inventory and receivables reserves, and the non-cash annual compensation charge, the Company would have reported a profit for the quarter. Cash and cash equivalents were $5.27 million, and current assets were $10.78 million, on February 28, 2021. Zack Irani, Chairman and Chief Executive Officer of Biomerica, commented, “This was a strong quarter for the Company. First and foremost, we’ve made great progress enrolling patients for our InFoods® IBS endpoint clinical trial in a tough pandemic environment, with some of the most respected healthcare institutions in the world, including Mayo Clinic, Beth Israel Deaconess Medical Center, Inc., a Harvard Medical School teaching Hospital, Houston Methodist, University of Texas Health Science Center at Houston, and the University of Michigan. While COVID-19 has delayed this clinical trial, we still expect to have top line analysis from this clinical trial by the end of the third calendar quarter of 2021. “InFoods® IBS is a patented product addressing the $30 billion Irritable Bowel Syndrome market where surprisingly little relief is currently available for patients. Our product is a disruptive technology redefining how patients with gastrointestinal diseases can be treated. InFoods® goes beyond simply treating symptoms of disease, it also is designed to help identify one of the underlying causes. If cleared, InFoods® IBS will be the first FDA-regulated diagnostic therapy identifying both the problematic foods of IBS patients, as well as alleviating the symptoms, offering broad appeal to patients, physicians and insurers. We are also excited to announce we now have six issued patents related to our InFoods® IBS product and platform technology, with many more in active prosecution and review. These patents should provide us strong protection from competition as we plan to launch these products into the market. “Alongside the progress we are making with InFoods®, the Biomerica team is working with leading institutions to quickly launch accurate COVID-19 tests while maintaining our commitment to providing these tests at a low cost,” Mr. Irani continued. “We have applied our technology and expertise to bring to market COVID-19 tests that drove significant revenue growth in the quarter, and we are encouraged by the traction we saw in Europe and look forward to expanding into other markets to bring our solution to more patients around the world. At the same time, the FDA continues to review our EUA submission for our products in the U.S. market. “While we are proud to be helping with the current global pandemic and believe that there are considerable revenue opportunities for testing around the world, it is important to note that our primary long-term focus continues to be on validation and commercialization of products based on our patented InFoods® technology platform. Our improved financial results in the quarter demonstrate the earnings leverage in our business model given our low-cost structure and focus on high ROI products. We continue to believe our InFoods® products could revolutionize the way people are treated for a variety of gastrointestinal diseases, while offering Biomerica sizable revenue opportunities,” Mr. Irani concluded. About Biomerica (NASDAQ: BMRA)Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primarily focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development. About InFoods®The Biomerica InFoods® IBS product is designed to allow physicians to identify patient-specific foods (e.g., eggs, broccoli, wheat, potatoes, corn, etc.), that when removed from the diet, may alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. This patented, diagnostic-guided therapy is designed to allow for a patient-specific, guided dietary regimen to improve IBS outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product is expected to be the first for which the Company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians' offices is already available for InFoods® diagnostic products. Since the InFoods® product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects. An estimated 45 million people in America currently suffer from IBS making it a leading cause for patient doctor visits. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the efficacy of the Company’s COVID-19 tests, FDA clearance, EUA clearance, the rapidity of testing results, uniqueness of a product, accuracy of products, pricing of the Company’s test kits, demand for international orders, availability of the Company’s COVID-19 test kits, and patent protection on the test technology. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of the Company’s COVID-19 tests; regulatory approvals necessary prior to commercialization of the Company’s COVID-19 tests; availability of the Company’s COVID-19 test kits; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various COVID-19 tests; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulations and the Company’s ability to obtain patent protection on any aspects of its rapid test technology. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release. 1. medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20047365. Accessed 15Jun20 Corporate Contact: John Nesbett /Jennifer BelodeauIMS Investor Relations203.email@example.com
Investor sentiment and perceived management tone register at record levels as revenue growth exuberance accelerates amid the vaccine rollout.
According to the new market research report "Artificial Intelligence (AI) in Medical Diagnostics Market by Component (Software, Service), Application (In Vivo, Radiology, OBGY, MRI, CT, Ultrasound, IVD), End User (Hospital, Diagnostic Laboratory, Diagnostic Imaging Center) – Global Forecast to 2025", published by MarketsandMarkets™, the global AI in Medical Diagnostics Market is projected to reach USD 3,868 million by 2025 from USD 505 million in 2020, at a CAGR of 50.2% during the forecast period.
Nulogy will extend its flexible cloud-based software as the global platform to digitalise the CEVA Logistics co-packing operations and enhance the firm's agility and responsiveness to its fast-moving consumer goods (FMCG) customers.
The AZEK Company Inc. (NYSE: AZEK) ("AZEK" or the "Company"), an industry-leading manufacturer of beautiful, low-maintenance and environmentally sustainable outdoor living and building products, including TimberTech® decking and Versatex® and AZEK Trim®, has named Sandra Lamartine as Senior Vice President and Chief Human Resources Officer.
Health Gorilla, a leader in clinical data APIs, and Triple-S, an independent licensee of the Blue Cross Blue Shield Association and the largest health insurance company in Puerto Rico, today announced a strategic collaboration to achieve bi-directional access to clinical data to improve quality, reduce costs, and improve the member experience.
No Cinco De Mayo celebration is complete without guacamole and Avocados From Mexico (AFM), the number one avocado brand in the U.S. To celebrate with consumers, AFM is launching a new 360 marketing campaign – Thank Guac It's Cinco (#TGICinco). The integrated campaign includes new television advertising, retailer partnerships to inspire avocado purchases and a branded digital hub offering customized guacamole recipes and chances to win prizes.
The Animal Feed Market Growth driven by rise in Industrial Livestock Production which has undergone substantial transformation owing to technological advancements in animal vaccinations and antibiotics.Pune, India, April 15, 2021 (GLOBE NEWSWIRE) -- Animal Feed Market: Key InsightsAccording to our new research study on “Animal Feed Market to 2027 – Global Analysis and Forecast – by Form and Livestock,” the Animal Feed Market was valued at US$ 406,640.10 million in 2018, and it is expected to grow at a CAGR of 3.3% during 2019–2027 to reach US$ 548,936.55 million by 2027. Increase in the demand for livestock products fuels the animal feed market growth. However, the implementation of stringent regulations in different regions is hampering the market growth. Animal Feed Market: Competition Landscape and Key DevelopmentsA few of the key players operating in the global animal feed market include Archer Daniels Midland Co.; Cargill Inc.; Evonik Industries AG; ForFarmers N.V.; Land O'Lakes, Inc.; Guangdong Haid Group Co. Ltd; New Hope Group Co. Ltd; Nutreco NV; and Perdue Farms, Inc. The major companies in the market are implementing strategies such as expansions and product launches to have wide geographic presence and clientele. For instance, in October 2019, Nutreco NV announced the acquisition of Animal Nutrition and Health (ANH), a South African premix company. This move would help Nutreco NV in underpinning its activities in South Africa, by allowing it to offer its leading product lines to a greater number of farms. Get Sample Pages of Animal Feed Market Research Report at https://www.theinsightpartners.com/sample/TIPRE00010192/ Asia Pacific held the largest share of the global animal feed market in 2018. The animal feed industry in countries of in this region has experienced a huge shift in consumption preferences over the years. Asia Pacific registers the fastest rate of production and consumption of pet food, which can be mainly attributed to increase in number of animal farms in the region. Moreover, shift in consumer living standards has propelled the pet owners to maintain the health of their pets. The region has emerged as one of the prominent importers of animal feed from western countries. China is dominating the animal feed market in Asia Pacific, followed by other countries such as Australia, Japan, India, Thailand, Malaysia, and Indonesia. Industrial livestock production has undergone substantial transformation owing to technological advancements in animal vaccinations and antibiotics, in terms of production and administration. According to the Food and Agriculture Organization (FAO), the industrial livestock production accounts for more than half of the world's pork and poultry, one-tenth of its beef and mutton, and more than two-thirds of its egg supply. The surge in the industrial production of mutton, beef, pork, and poultry, compared to the production through grazing and mixed farming, has escalated the demand for high-grade animal feed products. Industrial livestock production ensures high volume of meat production at low cost by leveraging the economies of scales. Thus, the crucial ability of industrial livestock production to meet the nutritional requirements of humans worldwide has led to the proliferation of industrial livestock farms across the world, thus augmenting the sales of animal feed. Download Sample PDF Brochure of Animal Feed Market Research Report at https://www.theinsightpartners.com/sample/TIPRE00010192/ Animal Feed Market: Segmental OverviewBased on form, the animal feed market is segmented into pellets, crumbles, mash, and others; the pellets segment dominated the market in 2018. The pellet form of feed ensures higher nutrition density, higher economic benefits, and more comprehensive nutrition. These pellets can be digested, absorbed, and conserved better by the feeding animals; moreover, they are easier to store and transport than other forms. Based on livestock, the animal feed market is segmented into poultry, ruminants, swine, aquaculture, and others. The poultry segment dominated the market in 2018. Poultry feed is food for farm chickens, ducks, geese, and other domestic birds. The common ingredients used in poultry feed are whole maize, cottonseed cake, maize germ, soya beans, sunflower, and fish meal (omen). Modern poultry feeds consist of grain; protein supplements, including soybean oil meal; mineral supplements; and vitamin supplements. Impact of COVID-19 Pandemic on Animal Feed MarketAs of March 2021, India, Brazil, Russia, China, Italy, Iran, Spain, the Republic of Korea, France, Germany, and the US are among of the worst-hit countries by the COVID-19 pandemic, in terms confirmed cases and reported deaths. The outbreak has been affecting economies and industries in various countries due to government impositions such as lockdowns and travel bans, and business shutdowns. Food and feed processing is one of the major industries suffering serious consequences of the pandemic in the form of supply chain breaks, technology events cancellations, office shutdowns, etc. Place a Direct Purchase Order for Animal Feed Market Research Study at https://www.theinsightpartners.com/buy/TIPRE00010192/ China is the global hub of manufacturing and largest raw material supplier for various industries, and it is also one of countries that faced early consequences of the outbreak. The lockdown of various plants and factories in China is affecting the global supply chains and hampering the manufacturing, delivery schedules, and sales. In addition, travel bans imposed by countries in Europe, Asia, and North America are affecting the business collaborations and partnerships opportunities. All these factors are limiting the animal feed and agriculture industry growth, thereby restraining the growth of other markets related to this industry. About Us:The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us:If you have any queries about this report or if you would like further information, please contact us: Contact Person: Sameer JoshiE-mail: firstname.lastname@example.orgPhone : +1-646-491-9876 Press Release - https://www.theinsightpartners.com/pr/animal-feed-market
With thousands of vital child care, school board and university workers still unable to obtain vaccinations to protect themselves from COVID-19, leaders from the Canadian Union of Public Employees (CUPE), who represent workers in those sectors, will today hold a virtual news conference to call for action from the Ford Government to protect more of the people whose work exposes them to the virus.
Aon plc (NYSE: AON), a leading global professional services firm providing a broad range of risk, retirement and health solutions, and Pentland Analytics, a provider of advanced analytics and advisory services to the executive management of the world's leading companies, today released "Respecting the Grey Swan," a new report detailing the impact crises have on reputation and shareholder value, and emphasizing the need for organizations to recalibrate their approach to risk and crisis in a highly volatile world.
Hyundai Motor will reveal the all-new 2022 Santa Cruz Sport Adventure Vehicle today during a world premiere in Tucson, Arizona. The Santa Cruz breaks new ground within the SUV, Truck and Crossover segments by offering a true Sport Adventure Vehicle unlike anything else in the U.S. market. Santa Cruz boasts bold yet sophisticated design, powerful and efficient powertrain options, a flexible open bed for gear, cutting-edge connectivity and a highly maneuverable all-wheel drive platform that is equally at home in urban and adventure-focused environments. Santa Cruz begins production in Montgomery, Alabama in June and will be available this summer. The Santa Cruz world premiere will take place today at 9:00 a.m. PT at:
MARIETTA, Pa., April 15, 2021 (GLOBE NEWSWIRE) -- Donegal Group Inc. (NASDAQ:DGICA) and (NASDAQ:DGICB), an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty lines of insurance in 24 Mid-Atlantic, Midwestern, New England, Southern and Southwestern states, reported today that its board of directors declared a regular quarterly cash dividend of $0.16 per share of the Company’s Class A common stock and $0.1425 per share of the Company’s Class B common stock. The dividends are payable on May 17, 2021 to stockholders of record as of the close of business on May 3, 2021. These dividends represent percentage increases of 6.7% for the Company’s Class A common stock and 7.5% for the Company’s Class B common stock compared to the previous quarterly cash dividend rates. Donegal Mutual Insurance Company and the insurance subsidiaries of Donegal Group Inc. conduct business together as the Donegal Insurance Group. The Donegal Insurance Group has an A.M. Best rating of A (Excellent). The Class A common stock and Class B common stock of Donegal Group Inc. trade on the NASDAQ Global Select Market under the symbols DGICA and DGICB, respectively. We are focused on several primary strategies, including achieving sustained excellent financial performance, strategically modernizing our operations and processes to transform our business, capitalizing on opportunities to grow profitably and delivering a superior experience to our agents and customers. For Further Information: Jeffrey D. MillerExecutive Vice President and Chief Financial OfficerPhone: (717) 426-1931E-mail: email@example.com Adam PriorSenior Vice President, The Equity Group Inc. Phone: (212) 836-9606 E-mail: firstname.lastname@example.org
A central message of the International Day of Light 2021 will encourage the public expression of confidence in the scientific process
SOUTHAMPTON, Pa., April 15, 2021 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (OTCQB: QNTO) (the "Company"), the holding company for Quaint Oak Bank, announced today that its Board of Directors at their meeting on April 14, 2021, declared a quarterly cash dividend of $0.11 per share on the common stock of the Company payable on May 10, 2021, to the shareholders of record at the close of business on April 26, 2021. Robert T. Strong, President and Chief Executive Officer stated, “I am pleased to announce the increase in our quarterly cash dividend moving from the current $0.09 per share to $0.11 per share. This represents a 22.2% increase in the dividend rate. The increased dividend is a reflection of our strong financial performance for fiscal 2020. As always, our current and continued business strategy includes long term profitability and the payment of dividends. This focus reflects the Company’s strong commitment to shareholder value.” Quaint Oak Bancorp, Inc. is the parent company for the Quaint Oak Family of Companies. Quaint Oak Bank, a Pennsylvania-chartered stock savings bank and wholly-owned subsidiary of the Company, is headquartered in Southampton, Pennsylvania and conducts business through three regional offices located in the Delaware Valley, Lehigh Valley and Philadelphia markets. Quaint Oak Bank’s subsidiary companies include Quaint Oak Abstract, LLC, Quaint Oak Insurance Agency, LLC, Quaint Oak Mortgage, LLC and Quaint Oak Real Estate, LLC. These subsidiary companies conduct business from numerous locations within the Bank’s market area. Additionally, the Bank holds a majority equity position in Oakmont Capital Holdings, LLC, a multi-state equipment finance company based in West Chester, Pennsylvania with a second significant facility located in Albany, Minnesota. Statements contained in this news release which are not historical facts may be forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words like “believe,” “expect,” “anticipate,” “estimate” and “intend” or future or conditional verbs such as “will,” “would,” “should,” “could” or “may.” We undertake no obligation to update any forward-looking statements. Contact: Quaint Oak Bancorp, Inc.Robert T. Strong, President and Chief Executive Officer(215) 364-4059
The drive for medical tourism has stemmed from the trend of improving patient care outcomes with the help of globalized access to health care. Medical tourism has reduced the wait times, substantially decreased the cost of quality medical care, and improved patient care in foreign countries. The medical tourism has made long-ranging impacts on the patient care in importing and exporting health care systems. For instance, sometimes, individuals seek medical care to a foreign nations because they are ineligible for the same in their countries.
The "Electronic Bill Presentment and Payment (EBPP) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.